2L therapy starts declining in territory
2L new starts declined from 48 to 46 over 8 weeks (-4.2%), indicating a conversion challenge rather than patient availability issue.
Source: Veeva CRM (C3M) Jan 2026
LECTRAZINE market share vs competitors
LECTRAZINE at 22.6% lags ZENOLIFT (26.6%), TETRAZINE (25.6%), and REVIVEX (25.1%), with persistent 2.7pp gap vs national average.
Source: DDD (C3M) Jan 2026
Eligible patient volume stable
Eligible patient pool grew from 847 to 863 patients over 4 months (+1.9%), confirming decline is not driven by patient availability.
Source: Veeva CRM (C3M) Jan 2026
Key HCPs 2L performance decline
Dr. Allen (-9.8%, 287 patients) leads decline, accounting for 42% of territory's total 2L drop despite representing only 31% of patient base.
Source: IQVIA Patients, DDD (C3M) Jan 2026
Territory payer mix distribution
Commercial (24.4%) and HIX (22.2%) dominate at 46.6% combined, with Commercial growing +1.6pp over past year while Medicare declined -1.6pp.
Source: IQVIA Claims Data (C3M) Jan 2026
Territory access mix breakdown
Only 22.2% have unrestricted access (down from 24.1%), while 53.4% face access barriers (PA 15.6%, Step 17.8%, Not Covered 20.0%).
Source: IQVIA Access Data (C6M) Jan 2026